Litigation Details for PAR STERILE PRODUCTS, LLC v. HARGAN (D.D.C. 2017)
✉ Email this page to a colleague
PAR STERILE PRODUCTS, LLC v. HARGAN (D.D.C. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-10-26 |
| Court | District Court, District of Columbia | Date Terminated | 2019-09-27 |
| Cause | 05:702 Administrative Procedure Act | Assigned To | Amit Priyavadan Mehta |
| Jury Demand | None | Referred To | |
| Patents | 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PAR STERILE PRODUCTS, LLC v. HARGAN
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for PAR STERILE PRODUCTS, LLC v. HARGAN (D.D.C. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-10-26 | External link to document | |||
| 2017-10-26 | 1 | five unexpired patents listed in FDA’s Orange Book, see U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209…approving drugs where certain patent disputes may arise. If an unexpired patent exists potentially covering…relevant patent owner to explain its invalidity or non-infringement rationale. And if the patent owner …the FDCA through the Drug Price Competition and Patent Term Restoration Act (the Hatch-Waxman amendments…follow-on version of Vasostrict® must comply with the patent-protection provisions of the FDCA applicable to | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
